Our findings suggest that targeting VEGFR1 may be a complementary strategy to anti-VEGF therapy, which is widely used to treat vascular disorders, including, age-related macular degeneration (AMD), DR, and DME. This evidence concerns the gene FLT1 and age-related macular degeneration.